text size  A   A

Rx Pharmaceutical Products

Lotemax (loteprednol etabonate ophthalmic ointment) 0.5%

Lotemax ointment is indicated to treat post-operative inflammation and pain following ocular surgery.¹ 

Lotemax Ointment
Lotemax ointment has proven efficacy in treating in treating inflammation and pain following surgery.  Ointment formulation provides additional choice in dosage forms for treating patients with ocular inflammation.2

Indication

  • Lotemax ointment is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery

Important Risk Information about Lotemax Ointment

  • Lotemax ointment, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
  • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored.
  • Use of corticosteroids may result in posterior subcapsular cataract formation and may delay healing and increase the incidence of bleb formation after cataract surgery. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after examination of the patient with the aid of magnification.  
  • Corticosteroids may increase the hazard of secondary ocular infections.  If pain, redness, itching or inflammation becomes aggravated, the patient should be advised to consult a physician.  If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. Fungal culture should be taken when appropriate.  
  • Patients should not wear contact lenses during their course of therapy with Lotemax ointment. Lotemax should not be used in children following ocular surgery as it may interfere with amblyopia treatment.  Lotemax is not indicated for intraocular administration. 
  • The most common ocular adverse event, reported in approximately 25% of subjects in clinical studies, is anterior chamber inflammation. Other common adverse events, with an incidence of 4-5%, are conjunctival hyperemia, corneal edema, and eye pain.  Many of these events may have been the consequence of the surgical procedure.

Please click here to view the Lotemax ointment full Prescribing Information.

References
1. Lotemax ophthalmic ointment Prescribing Information, April 2011.
2. Fiscella RG. Ophthalmic drug formulations. In: Barlett JD, Jaanus SD, eds. Clinical Ocular Pharmacology. 5 ed. St.Louis, MO: Butterworth-Heinemann; 2008:17-38.

US/LGX/12/0052(1)

Learn More

Visit LEmolecule.com